title: Clinical use of pasireotide for Cushing's disease in adults.
abstract: CUSHING’S DISEASE: Excessive corticotroph hormone levels sustained by an adrenocorticotropic hormone-secreting pituitary adenoma lead to a severe clinical condition caused by excess cortisol secretion, called Cushing's disease (CD). Neurosurgery and radiotherapy are used to treat the pituitary adenoma directly, but new medical treatments targeting the corticotroph cells have recently become available.
  This is a novel multireceptor ligand somatostatin (SST) analog with a high binding affinity for SST receptor 5, the predominant receptor in human corticotroph adenomas that is not downregulated by high cortisol levels (as SST receptor 2 is). Pasireotide has been recently approved by the European Medical Agency and the US Food and Drug Administration for treating adults with CD with recurrent hypercortisolism after surgery, or for whom surgery is not an option. A dose of 600-1,200 μg twice a day can normalize urinary free cortisol levels after 3 months of treatment in up to 28% of patients, reducing their blood pressure and improving their weight, lipid profile, and quality of life. Combining pasireotide with cabergoline to achieve a greater hormone response can normalize cortisol secretion in 50% of patients, and adding ketoconazole induces biochemical control in most patients with CD.
  The adverse effects of pasireotide are similar to those of other SST analogs, including diarrhea, nausea, and biliary sludge or gallstones. Hyperglycemia is common during pasireotide treatment, which affects the secretion of pancreatic insulin and intestinal glucagon-like peptide 1. Self-monitoring is essential to achieve good metabolic control, and endocrinologists should first administer metformin if insulin resistance is evident and then add dipeptidyl peptidase 4 inhibitors/glucagon-like peptide 1 receptor agonists or insulin.
  
  
  CONCLUSIONS
  In recent years, medical treatment with pasireotide has been proposed as monotherapy for adults with CD characterized by mild to moderate hypercortisolemia, as well as in combination with other available therapies. It is generally well-tolerated, but endocrinologists need to monitor glucose levels to ensure prompt treatment.
authors.affiliation: Endocrinology Unit, Department of Medicine, Padova University Hospital, Padova, Italy.
authors.forename: Filippo
authors.initials: F
authors.lastname: Ceccato
authors.affiliation: Endocrinology Unit, Department of Medicine, Padova University Hospital, Padova, Italy.
authors.forename: Carla
authors.initials: C
authors.lastname: Scaroni
authors.affiliation: Endocrinology Unit, Department of Medicine, Padova University Hospital, Padova, Italy.
authors.forename: Marco
authors.initials: M
authors.lastname: Boscaro
keywords: Cushing’s disease; hyperglycemia; medical therapy; pasireotide; safety
references.citation: Pituitary. 2015 Jun;18(3):359-65
references.pmid: 24952218
references.citation: Pituitary. 2014 Dec;17(6):519-29
references.pmid: 24287689
references.citation: Ann Intern Med. 2007 Oct 16;147(8):541-8
references.pmid: 17938392
references.citation: Curr Opin Endocrinol Diabetes Obes. 2013 Aug;20(4):330-4
references.pmid: 23807605
references.citation: Diabetes Res Clin Pract. 2014 Mar;103(3):458-65
references.pmid: 24461109
references.citation: J Clin Endocrinol Metab. 2009 Jan;94(1):223-30
references.pmid: 18957500
references.citation: Arq Bras Endocrinol Metabol. 2007 Nov;51(8):1339-48
references.pmid: 18209872
references.citation: J Clin Endocrinol Metab. 2014 Apr;99(4):1375-83
references.pmid: 24423285
references.citation: N Engl J Med. 2010 May 13;362(19):1846-8
references.pmid: 20463350
references.citation: J Clin Endocrinol Metab. 2012 Oct;97(10):3467-75
references.pmid: 22767639
references.citation: Clin Endocrinol (Oxf). 2013 Sep;79(3):394-401
references.pmid: 23278711
references.citation: Am J Physiol Endocrinol Metab. 2005 Aug;289(2):E278-87
references.pmid: 15769796
references.citation: J Clin Endocrinol Metab. 2011 Sep;96(9):2796-804
references.pmid: 21752886
references.citation: J Clin Pharmacol. 2014 Nov;54(11):1308-17
references.pmid: 24800725
references.citation: Diabetes Care. 2012 Jun;35(6):1364-79
references.pmid: 22517736
references.citation: Eur J Endocrinol. 2013 Jun 01;169(1):31-6
references.pmid: 23610124
references.citation: Pituitary. 2010 Jun;13(2):123-9
references.pmid: 19943118
references.citation: Eur J Endocrinol. 2010 Nov;163(5):709-16
references.pmid: 20702648
references.citation: Pituitary. 2014 Apr;17(2):187-95
references.pmid: 23564339
references.citation: Stereotact Funct Neurosurg. 2004;82(5-6):254-62
references.pmid: 15665560
references.citation: Clin Endocrinol (Oxf). 2014 Sep;81(3):408-17
references.pmid: 24533697
references.citation: Clin Endocrinol (Oxf). 2014 Jan;80(1):1-12
references.pmid: 24118077
references.citation: Neuroendocrinology. 2010;92 Suppl 1:107-10
references.pmid: 20829629
references.citation: J Clin Endocrinol Metab. 2012 Oct;97(10):3577-83
references.pmid: 22851491
references.citation: J Clin Endocrinol Metab. 2009 Sep;94(9):3121-31
references.pmid: 19734443
references.citation: Endocrine. 2014 Sep;47(1):9-20
references.pmid: 24415169
references.citation: Eur J Endocrinol. 2014 Jul;171(1):89-98
references.pmid: 24760537
references.citation: N Engl J Med. 2012 Mar 8;366(10):914-24
references.pmid: 22397653
references.citation: Drug Des Devel Ther. 2012;6:71-9
references.pmid: 22573933
references.citation: Eur J Endocrinol. 2014 Jul;171(1):1-7
references.pmid: 24743401
references.citation: Trends Endocrinol Metab. 2011 Dec;22(12):499-506
references.pmid: 21993190
references.citation: Eur J Endocrinol. 2008 Jan;158(1):91-9
references.pmid: 18166822
references.citation: Nat Rev Endocrinol. 2014 Apr;10(4):243-8
references.pmid: 24566817
references.citation: J Clin Endocrinol Metab. 2014 May;99(5):1623-30
references.pmid: 24471573
references.citation: J Neuroendocrinol. 2007 Jul;19(7):552-9
references.pmid: 17561883
references.citation: J Clin Endocrinol Metab. 2009 Jan;94(1):115-22
references.pmid: 18957506
references.citation: Eur J Endocrinol. 2002 May;146(5):707-16
references.pmid: 11980628
references.citation: Eur J Endocrinol. 2008 May;158(5):623-30
references.pmid: 18426820
references.citation: Clin Endocrinol (Oxf). 2006 Feb;64(2):219-24
references.pmid: 16430724
references.citation: J Clin Endocrinol Metab. 2008 May;93(5):1526-40
references.pmid: 18334580
references.citation: Eur J Endocrinol. 2012 May;166(5):821-8
references.pmid: 22383336
references.citation: J Intern Med. 2014 Feb;275(2):104-15
references.pmid: 24330030
references.citation: Pituitary. 2015 Feb;18(1):60-7
references.pmid: 24482099
references.citation: Pituitary. 2014 Apr;17(2):180-6
references.pmid: 23564338
references.citation: Pituitary. 2014 Apr;17(2):109-17
references.pmid: 23468128
references.citation: J Mol Endocrinol. 2014 Jun;52(3):R223-40
references.pmid: 24647046
references.citation: J Clin Endocrinol Metab. 2008 Jul;93(7):2454-62
references.pmid: 18413427
references.citation: Eur J Endocrinol. 2013 Dec 21;170(2):283-92
references.pmid: 24217937
references.citation: Endocrinology. 2014 Sep;155(9):3538-49
references.pmid: 24926820
references.citation: Cancer Chemother Pharmacol. 2013 Aug;72(2):387-95
references.pmid: 23765178